Published in J Acquir Immune Defic Syndr on December 01, 2010
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J (2013) 1.27
Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis (2015) 1.13
Improving public health through access to and utilization of medication assisted treatment. Int J Environ Res Public Health (2011) 0.90
Prevention and treatment of HIV/AIDS among drug-using populations: a global perspective. J Acquir Immune Defic Syndr (2010) 0.90
Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr Dis Treat (2014) 0.90
Tuberculosis screening in a novel substance abuse treatment center in Malaysia: implications for a comprehensive approach for integrated care. J Subst Abuse Treat (2013) 0.83
Coexisting social conditions and health problems among clients seeking treatment for illicit drug use in Finland: the HUUTI study. BMC Public Health (2013) 0.83
Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend (2011) 0.81
Enhanced tuberculosis case detection among substitution treatment patients: a randomized controlled trial. BMC Res Notes (2011) 0.80
Prevalence of hepatitis C virus and human immunodeficiency virus in a group of patients newly diagnosed with active tuberculosis in Porto Alegre, Southern Brazil. Mem Inst Oswaldo Cruz (2017) 0.75
A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia. PLoS One (2017) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet (2006) 21.60
A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med (1989) 10.98
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Epidemiology of hepatitis C virus infection. World J Gastroenterol (2007) 7.36
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med (2009) 4.76
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ (2009) 2.69
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med (2009) 2.16
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med (2001) 2.12
Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep (2007) 2.04
Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr (2009) 2.01
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis (2008) 1.86
High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J Acquir Immune Defic Syndr (2002) 1.75
Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr (2006) 1.73
Rifampin-induced methadone withdrawal. N Engl J Med (1976) 1.70
Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy (2007) 1.65
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother (2006) 1.58
Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clin Infect Dis (2010) 1.47
Reported HIV status of tuberculosis patients--United States, 1993-2005. MMWR Morb Mortal Wkly Rep (2007) 1.45
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 1.42
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat (2008) 1.40
Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep (2000) 1.39
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis (2008) 1.26
Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat (2007) 1.20
Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis (2007) 1.18
Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin Infect Dis (2005) 1.15
Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS (2009) 1.10
Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med (2006) 1.09
Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis (2006) 1.08
Tuberculosis, drug resistance, and HIV/AIDS: a triple threat. Curr Infect Dis Rep (2007) 1.00
Hepatitis C virus infection in Eastern Europe. J Hepatol (1999) 0.93
High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat (2010) 0.85
Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Rev Clin Pharmacol (2008) 0.84
Drug interactions of clinical importance with methadone and buprenorphine. Am J Addict (2010) 0.81
Hepatitis C virus infection in HIV-infected patients. Curr HIV/AIDS Rep (2004) 0.77